Predict your next investment

Regentis Biomaterials company logo
HEALTHCARE | Drug Development
regentis.co.il

See what CB Insights has to offer

Founded Year

2004

Stage

Grant | Alive

Total Raised

$32.5M

About Regentis Biomaterials

Regentis Biomaterials is focused on developing and commercializing hydrogels for tissue regeneration. The Gelrin hydrogel platform is a matrix of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen, combining the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications. The company's flagship product, GelrinC, for the treatment of articular cartilage lesions, is currently in clinical trials.

Regentis Biomaterials Headquarter Location

Northern Industrial Zone 12 Ha’ilan Street

Or Akiva, 3060000,

Israel

+972-4-6265502

Latest Regentis Biomaterials News

TRIA Orthopedics First in Minnesota to Test Breakthrough GelrinC™ Implant to Regenerate Knee Cartilage

Nov 27, 2018

November 27, 2018 09:00 AM Eastern Standard Time MINNEAPOLIS--( BUSINESS WIRE )--Regentis Biomaterials today announced that Twin Cities-based TRIA Orthopedics is the first in Minnesota to perform a procedure using the GelrinC ™ implant to treat damaged articular cartilage causing knee pain. GelrinC (pronounced “gel-rin-cee”) is an investigational device being evaluated as a treatment to help the body regrow cartilage in the knee. TRIA is the only site in Minnesota – and just one of 17 sites nationwide – enrolling patients with knee pain caused by damaged knee cartilage in the SAGE clinical trial. Articular cartilage is the smooth, white tissue covering the ends of bones where they come together to form joints. Damage to the cartilage layer can be extremely painful for patients and is generally associated with sudden trauma. Surgical intervention is often required because of the limited capacity for cartilage to repair itself. The current standard of care is a procedure called microfracture, which involves making tiny holes in the bone underneath the damaged cartilage to stimulate the growth of new cartilage. However, the cartilage is more like scar tissue than the original hyaline cartilage; as a result, microfracture often provides only short-term relief and may require repeat surgeries. “There are limited options for patients who continue to experience knee pain caused by damage to their articular cartilage,” said Dr. Brad Nelson, orthopedic surgeon. “The hope is that GelrinC, which requires only a single minimally invasive procedure, will promote repair of the cartilage and alleviate pain.” People 18-50 years old with pain in one knee caused by damaged articular cartilage can inquire about the study by visiting www.MyKneeStudy.com or by calling (833) 430-8686. About GelrinC™ In the U.S., GelrinC™ from Regentis Biomaterials is an investigational device for patients with articular cartilage damage in their knee. GelrinC’s unique mode of action allows it to be implanted as a liquid so that it completely fills the cartilage defect in the knee, and then be cured into a gel that enables the body’s own stem cells to settle on its surface. Six to 12 months after surgery, the GelrinC is gradually resorbed by the body and replaced by new cartilage tissue. Preliminary clinical trials in Europe have indicated that this regenerated tissue provides excellent improvement in pain and function. To learn more about GelrinC, please visit www.GelrinC.com . About the SAGE Clinical Trial The SAGE study is a Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical study comparing GelrinC to microfracture, the current standard of care treatment for damaged knee cartilage. The multi-center Phase III pivotal study will enroll 120 patients. All patients who meet study requirements and agree to enter the trial are provided GelrinC as treatment. About Regentis Biomaterials With offices in Princeton, New Jersey, and Or Akiva, Israel, Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The technology was originally developed at the Technion-Israel Institute of Technology by Dr. Dror Seliktar. For more information, please visit www.regentis.co.il . CAUTION Investigational device. Limited by United States law to investigational use. Contacts Joni Ramirez

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Regentis Biomaterials

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Regentis Biomaterials is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

M

Medical Devices

7,891 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Regentis Biomaterials Patents

Regentis Biomaterials has filed 16 patents.

The 3 most popular patent topics include:

  • Arthritis
  • Biomaterials
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/26/2014

10/8/2019

Biomaterials, Polymers, Tissue engineering, Colloidal chemistry, Polymer chemistry

Grant

Application Date

6/26/2014

Grant Date

10/8/2019

Title

Related Topics

Biomaterials, Polymers, Tissue engineering, Colloidal chemistry, Polymer chemistry

Status

Grant

Regentis Biomaterials Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Regentis Biomaterials Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.